Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
Authors
Keywords
-
Journal
International Journal of Environmental Research and Public Health
Volume 16, Issue 22, Pages 4334
Publisher
MDPI AG
Online
2019-11-07
DOI
10.3390/ijerph16224334
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension
- (2019) Guadalupe Garcia-Tsao et al. JOURNAL OF HEPATOLOGY
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
- (2018) Eric J. Lawitz et al. Clinical Gastroenterology and Hepatology
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
- (2018) Donghee Kim et al. Clinical Gastroenterology and Hepatology
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH
- (2018) Eric Lawitz et al. GASTROENTEROLOGY
- Therapy for steatohepatitis: Do macrophages hold the clue?
- (2018) Reben Raeman et al. HEPATOLOGY
- Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
- (2018) Leigh Goedeke et al. HEPATOLOGY
- Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
- (2018) Oliver Krenkel et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- BMS-986036, a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and Pro-C3 in a mouse model of non-alcoholic steatohepatitis
- (2018) Y. Luo et al. JOURNAL OF HEPATOLOGY
- MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
- (2018) S. Harrison et al. JOURNAL OF HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
- (2018) James S.V. Lally et al. Cell Metabolism
- Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension
- (2018) Guadalupe Garcia-Tsao et al. HEPATOLOGY
- Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
- (2018) Mitchell Shiffman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
- (2018) Eduardo Vilar-Gomez et al. HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Low Vitamin E Levels in NAFLD Patients are Associated with Increased All-Cause Mortality: A 23-Year Prospective Population-Based Study
- (2017) Kimberly Daniel et al. GASTROENTEROLOGY
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study
- (2017) Kathryn Stiede et al. HEPATOLOGY
- Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials
- (2017) A. Sanyal et al. JOURNAL OF HEPATOLOGY
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Pharmacological aspects of the safety of gliflozins
- (2017) Jean-Luc Faillie PHARMACOLOGICAL RESEARCH
- Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver
- (2017) Federico Salomone et al. Nutrients
- Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice
- (2017) Koki Obara et al. Oncotarget
- Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
- (2017) Tobias Puengel et al. PLoS One
- A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
- (2016) Melanie Thompson et al. AIDS
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies
- (2016) Cynthia Ju et al. Cellular & Molecular Immunology
- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
- (2016) Scott Friedman et al. Contemporary Clinical Trials
- Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
- (2016) E Lefebvre et al. CTS-Clinical and Translational Science
- An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
- (2016) Cen Xie et al. DIABETES
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study
- (2016) Dong Hyun Sinn et al. GUT
- Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury
- (2016) Jana C. Mossanen et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
- (2016) Stefano Ballestri et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
- (2016) Amalia Gastaldelli et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Fibroblast Growth Factor Signaling in Metabolic Regulation
- (2016) Vera J. M. Nies et al. Frontiers in Endocrinology
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
- (2016) Eric Lefebvre et al. PLoS One
- Bile Acids as Hormones: The FXR-FGF15/19 Pathway
- (2015) Steven A. Kliewer et al. DIGESTIVE DISEASES
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists
- (2015) David E. Kleiner et al. GASTROENTEROLOGY
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
- (2014) M. Zhou et al. CANCER RESEARCH
- Nuclear Receptors, RXR, and the Big Bang
- (2014) Ronald M. Evans et al. CELL
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
- (2014) Fernando J. Barreyro et al. LIVER INTERNATIONAL
- Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review
- (2014) Ahad Eshraghian WORLD JOURNAL OF GASTROENTEROLOGY
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Bile acid receptors in non-alcoholic fatty liver disease
- (2013) Yuanyuan Li et al. BIOCHEMICAL PHARMACOLOGY
- Pleiotropic Roles of Bile Acids in Metabolism
- (2013) Thomas Q. de Aguiar Vallim et al. Cell Metabolism
- An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
- (2013) William L. Holland et al. Cell Metabolism
- Peroxisome proliferator-activated receptor δ
- (2013) Lazar A. Bojic et al. CURRENT OPINION IN LIPIDOLOGY
- Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
- (2013) Lucia Carulli et al. CURRENT PHARMACEUTICAL DESIGN
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway
- (2013) Yongxiang Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
- (2013) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association
- (2012) Naga Chalasani et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Therapeutic targets in the ASK1-dependent stress signaling pathways
- (2012) Ryoichi HAYAKAWA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Prevalence of Hypothyroidism in Nonalcoholic Fatty Liver Disease
- (2011) Mangesh R. Pagadala et al. DIGESTIVE DISEASES AND SCIENCES
- Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
- (2011) Clarence Hale et al. ENDOCRINOLOGY
- Vitamin E and the Risk of Prostate Cancer
- (2011) Eric A. Klein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Silybin and the liver: From basic research to clinical practice
- (2011) Carmela Loguercio WORLD JOURNAL OF GASTROENTEROLOGY
- Clinical trial: efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C
- (2010) M. L. SHIFFMAN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
- (2010) Gökhan S. Hotamisligil CELL
- Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease
- (2010) R. N. Hardwick et al. DRUG METABOLISM AND DISPOSITION
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and Mortality
- (2010) Nicolas Rodondi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apoptosis and Cytokines in Non-Alcoholic Steatohepatitis
- (2009) Wing-Kin Syn et al. Clinics in Liver Disease
- Free Fatty Acids Link Metabolism and Regulation of the Insulin-Sensitizing Fibroblast Growth Factor-21
- (2009) K. Mai et al. DIABETES
- Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells
- (2009) Marco Trappoliere et al. JOURNAL OF HEPATOLOGY
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- (2008) Justin I. Odegaard et al. Cell Metabolism
- Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
- (2008) J. Xu et al. DIABETES
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Fibroblast Growth Factor 21 Corrects Obesity in Mice
- (2008) Tamer Coskun et al. ENDOCRINOLOGY
- Treatment of preestablished diet-induced fatty liver by oral fatty acid–bile acid conjugates in rodents
- (2008) Alicia Leikin-Frenkel et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Olmesartan Prevents Cardiovascular Injury and Hepatic Steatosis in Obesity and Diabetes, Accompanied by Apoptosis Signal Regulating Kinase-1 Inhibition
- (2008) Eiichiro Yamamoto et al. HYPERTENSION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now